Shanghai Haohai Biological Technology Co., Ltd. (SEHK: 6826)
Health Care · Biotechnology · CN
HK$16.11
+0.25% today · -38.6% 1Y
Shanghai Haohai Biological Technology Co., Ltd. (SEHK: 6826) operates in the Biotechnology industry within the Health Care sector. The company is valued at $943.26M and employs 1,999 people.
Over the last twelve months the share price has lost 38.6%, trading between 15.04 and 30.68.
Tweenvest scores Shanghai Haohai Biological Technology Co., Ltd. across four factors: quality 72/100, value 66/100, growth 30/100, dividend 85/100. Its strongest factor is dividend.
6826 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $943.26M
- Revenue (TTM)
- $341.69M
- P/E
- 21.11
- EPS
- 0.66
- Dividend yield
- 7.28%
- Beta (5Y)
- 0.45
- 52-week high
- HK$30.68
- 52-week low
- HK$15.04
- Avg volume (3M)
- —
- Shares outstanding
- 224.05M
- Employees
- 1,999
- Next earnings
- —
About Shanghai Haohai Biological Technology Co., Ltd.
Shanghai Haohai Biological Technology Co., Ltd. is a global enterprise dedicated to the research, development, manufacturing, and commercialization of biomedical materials. Its operations span Mainland China, the United States, the United Kingdom, and various other international regions. A comprehensive product portfolio addresses several key medical disciplines. Within ophthalmology, offerings include intraocular lenses, ophthalmic viscoelastic devices, orthokeratology and phakic refractive lenses, eye drops, injectors, and surgical scalpels. Orthopedics products encompass sodium hyaluronate injections and medical chitosan. For wound repair, it manufactures recombinant human epidermal growth factor, effective in treating burn wounds, residual wounds, donor site post-traumatic wounds, and both fresh and chronic ulcerations. Additionally, the company develops anti-adhesion materials, including medical sodium hyaluronate gel and medical chitosan, as well as hemostatic solutions such as collagen sponges and porcine fibrin sealants. Beyond its therapeutic offerings, Shanghai Haohai maintains a significant presence in the medical aesthetics market. This segment features a range of hyaluronic acid (HA) dermal fillers: Matrifill, positioned as a first-generation mono-phase injectable HA gel; Janlane, a second-generation filler engineered for dynamic application; and Hyalumatrix, a third-generation product providing precise aesthetic embellishment. Its aesthetic portfolio is further complemented by radio frequency devices and laser equipment. Furthermore, the company actively engages in the research and development of biological engineering and pharmaceutical products, extending services such as technology transfer and consultation. It also conducts investment and trading operations. Established in 2007, the entity initially traded as Haohai Limited before officially adopting the name Shanghai Haohai Biological Technology Co., Ltd. in 2010. Its corporate headquarters are based in Shanghai, China.
- ISIN
- CNE100001W69
- Founded
- 2007
- Listed since
- Apr 30, 2015
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Cullinan Therapeutics, Inc.NasdaqGS: CGEM | $999.43M | $15.53 | +0.45% |
| Philogen S.p.A.BIT: PHIL | $991.45M | €22.00 | +0.69% |
| Jiangsu Aidea Pharmaceutical Group Co., Ltd.SHSE: 688488 | $989.43M | CN¥15.75 | -5.29% |
| Basilea Pharmaceutica AGSWX: BSLN | $979.21M | CHF65.50 | -1.95% |
| Kura Oncology, Inc.NasdaqGS: KURA | $942.98M | $10.60 | +0.76% |
| Ascletis Pharma Inc.SEHK: 1672 | $936.85M | HK$6.96 | -14.23% |
| Ingenia Therapeutics Inc.KOSDAQ: A950260 | $932.34M | ₩25,350.00 | -12.13% |
| LongBio Pharma (Suzhou) Co., Ltd.SEHK: 1779 | $926.52M | HK$98.00 | -3.64% |
Figures last refreshed Oct 11, 2026.